一项新研究表明，一种低成本药物可能有助于那些尽管接受治疗但血压仍居高不下的中风幸存者。
A low-cost medication could help stroke survivors whose blood pressure remains elevated despite treatment, a new study suggests.
这项名为REDUCE试验的研究，旨在探讨在常规治疗基础上加用螺内酯——一种俗称“利尿剂”的药物——是否有助于降低中风后的血压。研究结果于2026年11月6日至9日在美国心脏协会科学年会上发布，会议在芝加哥举行。
The research, known as the REDUCE trial, looked at whether adding spironolactone, a medication commonly known as a water pill, could help lower blood pressure after a stroke. The findings were presented at the American Heart Association's Scientific Sessions, Nov. 6-9, 2026, in Chicago.
参与者被分为两组。一组在常规治疗基础上加用螺内酯，另一组继续接受常规的中风后护理。
Participants were split into two groups. One added spironolactone to their regular treatment, while the other continued with usual post-stroke care.
研究人员在随后的六个月里追踪参与者的家庭血压，以确定加用该药物是否有效。
Researchers tracked the participants' blood pressure at home over the following six months to determine whether adding the medication made a difference.
研究称，三个月后，服用螺内酯人群的平均收缩压（高压）比接受常规护理人群低近8个点——约为126毫米汞柱，对比133毫米汞柱。
After three months, the top blood pressure number was nearly eight points lower on average among people taking spironolactone compared with those receiving usual care – about 126 versus 133, the study said.
达到推荐血压目标（低于130/80毫米汞柱）的患者，服药组也更多。服药组有52%达标，而常规护理组为30%。
More patients taking spironolactone also reached the recommended blood pressure goal of less than 130/80. That included 52% of those taking the medication compared with 30% receiving usual care.
研究共同第一作者、宾夕法尼亚大学医学与流行病学副教授Jordana Cohen博士在新闻稿中说：“降低血压是预防再次中风最重要的一步，但许多中风幸存者在中风后难以达到推荐的血压目标。”
"Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended blood pressure targets after a stroke," study co-lead author Dr. Jordana Cohen, an associate professor of medicine and epidemiology at the University of Pennsylvania, said in a news release.
她补充道：“当螺内酯被加入中风后护理方案时，我们观察到血压有显著下降，这可能降低未来中风和心脏病发作的风险。”
"When spironolactone was added to post-stroke care, we saw a meaningful drop in blood pressure that may lower the risk of future strokes and heart attacks," she added.
未参与该研究的加利福尼亚州执业急诊医学专科医生、前首席医疗官Alfred Joshua博士表示，这些发现令人鼓舞，但目前尚未显示该药物能预防后续中风。
Dr. Alfred Joshua, a California-based board-certified emergency physician and former chief medical officer who was not involved in the research, said the findings are encouraging, but do not yet show that the medication prevents a subsequent stroke.
“我们已经知道，控制血压可以降低再次中风的风险，”约书亚对福克斯新闻数字版表示。“这项研究测量了血压，因此增加螺内酯是否能减少复发性中风仍是一个悬而未决的问题。”根据美国国家医学图书馆的资料，螺内酯通过帮助身体排出多余的盐和水来发挥作用，从而降低血压。该药物的处方信息指出，它还会导致身体潴留钾，因此服用该药的患者需要检查钾水平。
"We already know that controlling blood pressure lowers the risk of another stroke," Joshua told Fox News Digital. "This study measured blood pressure, so whether adding spironolactone leads to fewer repeat strokes is still an open question." Spironolactone works by helping the body get rid of extra salt and water, which can lower blood pressure, according to the U.S. National Library of Medicine. It also causes the body to hold onto potassium, so patients taking it need to have their levels checked, the drug’s prescribing information states.
约书亚警告说，高钾血症是主要的安全顾虑之一，因为它可能在没有症状的情况下发生。对于有肾脏问题以及服用某些药物或钾补充剂的人群，风险可能更高。他补充说，该药物还可能将血压降低到足以导致头晕的程度。
Joshua warned that high potassium is one of the main safety concerns because it can develop without symptoms. The risk can be higher for people with kidney problems and those taking certain medications or potassium supplements. The medication can also lower blood pressure enough to cause dizziness, he added.
“如果您中风后血压仍然偏高，请将家庭测量的读数带给您的临床医生，询问这种药物是否适合您，”约书亚建议道。
"If your blood pressure is still high after a stroke, bring your home readings to your clinician and ask whether this medication is a good fit," Joshua advised.
研究人员指出，该试验提前结束，入组了160名参与者，而非原计划的200名，且约15%的参与者在三个月时点没有可用的血压读数。
The trial ended early with 160 participants instead of the planned 200, and about 15% did not have blood pressure readings available at the three-month mark, the researchers noted.
服用螺内酯的人群总体上服用的降压药物也比接受常规治疗组的人略多。
People taking spironolactone were also taking slightly more blood pressure medications overall than those receiving usual care.
研究人员表示，该研究并非旨在确定螺内酯是否真能预防再次中风或心脏病发作。要回答这个问题，还需要更大规模、更长时间的研究。福克斯新闻数字版已联系研究人员置评。
The study was not designed to determine whether spironolactone actually prevents another stroke or heart attack. Larger and longer studies are needed to answer that question, according to the researchers. Fox News Digital reached out to the researchers for comment.